who owns the patent for retatrutide Retatrutide: Eli Lilly's Bold Gamble Biologic Status – What It Means for Future of Obesity Treatment 🎥 Eli Lilly’s next generation

More recent agents include dual agonists such as tirzepatide, which activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and produces even greater weight loss

Certain conditions make microneedling inadvisable, including active acne breakouts in the treatment area, active infections or cold sores, certain skin diseases, blood-clotting disorders, or pregnancy

NICE guidance on obesity management emphasises individualised treatment decisions, weighing potential benefits against risks for each patient

Looking Ahead In my next article, Ill dive deeper into specific exercise recommendations for individuals who are overweight, obese, or experiencing extreme obesityincluding safety tips and tailored routines

To ensure transparency and address the completeness of the data presentation, representative full-membrane images have been included in the Supplementary File accompanying this paper

PracticalCME has taught evidence-based weight loss since 2008, long before GLP-1 medications dominated the field